An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Phase of Trial: Phase III
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 03 Mar 2017 Status changed from active, no longer recruiting to completed.
- 06 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Feb 2017.
- 06 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Feb 2017.